Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO

AACHEN, Germany, February 1, 2018 /PRNewswire/ -- Grünenthal announced today that Adhesys Medical Inc., a wholly-owned subsidiary of Grünenthal, has been granted Expedited Access Pathway (EAP) designation by the U.S. Food and Drug Administration (FDA) for VIVO. VIVO is a surgical...

from PR Newswire: //http://ift.tt/2DNOwIz